Free Trial
OTCMKTS:NGENF

NervGen Pharma (NGENF) Stock Price, News & Analysis

NervGen Pharma logo
$2.15 +0.01 (+0.56%)
As of 04/25/2025 03:58 PM Eastern

About NervGen Pharma Stock (OTCMKTS:NGENF)

Key Stats

Today's Range
$2.14
$2.16
50-Day Range
$1.81
$2.27
52-Week Range
$1.20
$2.42
Volume
39,435 shs
Average Volume
58,071 shs
Market Capitalization
$132.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Receive NGENF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NervGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

NGENF Stock News Headlines

NervGen Pharma to Host Virtual Investor Event
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
NervGen Pharma price target raised to C$4.50 from C$3 at Raymond James
NervGen upgraded to Outperform from Market Perform at Raymond James
See More Headlines

NGENF Stock Analysis - Frequently Asked Questions

NervGen Pharma's stock was trading at $2.18 at the start of the year. Since then, NGENF stock has decreased by 1.4% and is now trading at $2.15.
View the best growth stocks for 2025 here
.

Shares of NGENF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:NGENF
CIK
N/A
Web
N/A
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$150,000.00
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$132.81 million
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (OTCMKTS:NGENF) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners